Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. van Lierop ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al. Mult Scler 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.

Read + Share

Amedeo Smart

Independent Medical Education

van Lierop ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, et al. Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. Mult Scler 2021 Apr 23:13524585211010097. doi: 10.1177/13524585211010097.
PMID: 33890520